1. How to submit my research paper? What’s the process of publication of my paper?
The journal receives submitted manuscripts via email only. Please submit your research paper in .doc or.pdf format to the submission email: ijlbpr@ejournal.net.
You’ll be given a paper number if your submission is successful. Your paper then will undergo peer review process, which may take approximately one and a half months under normal circumstances, three tops.
After blind peer review, you will receive the notification letter with the review result of your paper...
2. Can I submit an abstract?
The journal publishes full research papers. So only full paper submission should be [Read More]

Safety and Efficacy of Tiotropium Bromide in Bronchial Asthma and COPD Patients, Cross Over Studies by Placebo

Sridevi K. 1, Vijaya N.2, G. Manoj Someswar 3, and MohanaRao V.4
1. Department of pharmacology, Rajiv Gandhi Institute of Medical Sciences, Kadapa, AP, India.
2. Department of Biochemistry & Molecular Biology, Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Hyderabad, AP, India.
3. Department of Pharmacology, Osmania Medical College, Hyderabad, AP, India.
4. Monco Biotechnologies Pvt. Limited, Ameerpet, Hyderabad, AP, India.
Abstract—Asthma attacks all age groups but often starts in childhood. It isa disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. According to WHO Between 100 and 150 million people around the globe -- roughly the equivalent of the population of the Russian Federation -- suffer from asthma and this number is rising. World-wide, deaths from this condition have reached over 180,000 annually. Asthma and COPD are clinically defined airway disorders that individually have significant heterogeneity with regard to underlying pathogenesis and responses to therapy. Tiotropium is well tolerated, with a safety profile comparable with that of placebo. The parasympathetic nervous system plays an important role in autonomic control of airways and is believed to be largely responsible for resting but they bronchomotor tone in COPD. Hence the purpose of the present study was to evaluate the efficacy and safety of 18mcg Tiotropium metered dose inhalation, administered once daily for 14 weeks in patients with COPD and Bronchial asthma, cross over study with placebo. The over all results of our study suggests that Tiotropium in the dose of 18 mcg once daily via dry powder inhaler result in 24 h bronchodilation as well as consistent and sustained improvement for both the COPD and the bronchial asthma patients. It is safe and efficacious drug both clinically and spirometrically. Our study showed decrease in symptoms, decrease in rescue medication frequency and also reduce frequency of acute attacks.

Index Terms—Bronchial asthma, COPD, Tiotropium, PLACEBO

Cite: Sridevi K., MohanaRao V., Vijaya N., and G. Manoj Someswar, "Safety and Efficacy of Tiotropium Bromide in Bronchial Asthma and COPD Patients, Cross Over Studies by Placebo," International Journal of Life Sciences Biotechnology and Pharma Research, Vol. 1, No. 4, pp. 250-262, October 2012.
Copyright © 2012-2015 International Journal of Life Sciences Biotechnology and Pharma Research, All Rights Reserved